A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

Refractory Diffuse Large B-Cell Lymphoma Clinical Trial

— C-CAR011  

Official title:

A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02976857
• Other study ID #: CBMG2016002
• Status: Completed
• Phase: Phase 1
• Start date: December 2016
• Est. completion date: January 9, 2019

Study information

• Verified date: November 2016
• Source: Cellular Biomedicine Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL

Description:

The 3x3 dose escalation design will be adopted in order to determine the maximum tolerated dose (MTD). Subjects will be enrolled into low-dose group, medium-dose group and high-dose group as below:

Dose CAR+ cells/kg

Low 0.8×106

Medium 2.5×106

High 5.0×106

DLT is evaluated within 30 days post C-CAR011 infusion).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 9, 2019
• Est. primary completion date: September 11, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Histologically diagnosed as DLBCL according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines (3rd edition 2016)

• Refractory DLBCL

• All subjects must have received adequate prior therapy including anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and an anthracycline containing chemotherapy regimen. The standardized treatment regimens reference to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2016 Version 3)

• At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor = 1.5 cm)

• Age 18-70 years old, male or female

• Expected survival = 12 weeks

• ECOG score 0-1

• Subject's left ventricular ejection fraction (LVEF) is = 50% and no evidence of pericardial effusion as determined by an ECHO

• At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments)

• No contraindications of peripheral blood apheresis

• Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial measures

• Volunteered to participate in this study and signed informed consent

Exclusion Criteria:

• Have a history of allergy to cellular products

• Used any genetically modified T cell therapy

• History of allogeneic hematopoietic stem cell transplantation

• Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis allowed) or currently receiving intravenous antibiotic therapy and received intravenous antibiotic therapy within one week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible

• Hepatitis B or hepatitis C virus infection (including carriers), as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons

• Patients with class III and IV heart failure according to the NYHA Heart Failure Classifications

• A history of QT prolongation

• A history of epilepsy or other central nervous system disorders

• The patient had a history of other primary cancers, with the following exceptions:

Excisional non-melanoma such as cutaneous basal cell carcinoma; Cured in situ carcinoma such as cervical cancer, bladder cancer or breast cancer

• Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy

• Used of systemic steroids within two weeks (using inhaled steroids is an exception)

• Women who are pregnant or lactating or have breeding intent in 6 months

• Participated in any other clinical trial within three months

• The investigators believe that any increase in the risk of the subject or interference with the results of the trial

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Refractory Diffuse Large B-Cell Lymphoma

Intervention

Biological:
• C-CAR-011
lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.

Locations

Country	Name	City	State
China	Hematological Department, People's Hospital of Jiangsu Province	Nanjing City	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Cellular Biomedicine Group Ltd.	The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity (DLT)	Non-haematological dose-limiting toxicities was any toxicity of grade 3 or higher occurring within 28 days of C-CAR011 infusion judged possibly related to the treatment regimen.The following toxicities were not considered dose limiting toxicities: tumor lysis syndrome, abnormal electrolytes responding to supplementation, hypoalbuminemia, liver dysfunction resolving to =grade 2 within 14 days, transient (<72 hours) grade 4 hepatic enzyme abnormality, and grade 3 or 4 fever or neutropenic fever.	28 days
Secondary	Overall response rate	Overall response rate (ORR) = complete response (CR) rate + partial response (PR) rate, ORR will be assessed at weeks 4 and weeks 12 according to International Working Group (IWG) revised criteria.	4 and 12 weeks
Secondary	Disease control rate	Disease control rate (DCR) = complete response (CR) rate + partial response (PR) rate + stable disease (SD) rate, DCR will be assessed at weeks 12 according to International Working Group (IWG) revised criteria.	12 weeks